CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medigen Vaccine Biologics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medigen Vaccine Biologics Corp
No.68
Shengyi 3rd Road, Hsinchu Science Park
Phone: +886 36684866p:+886 36684866 ZHUBEI, 302  Taiwan Ticker: 65476547
Business Summary
Medigen Vaccine Biologics Corp is a Taiwan-based company principally engaged in the development and manufacture of vaccines and biological agents. The Company is engaged in the research, design, development, manufacture, and sale of cell culture vaccines such as influenza vaccines, enterovirus vaccines and dengue vaccines, as well as other biological agents. The main products include enterovirus 71 vaccines (Envacgen), quadrivalent seasonal influenza vaccines, and coronavirus disease 2019 (COVID-19) vaccines. The Company primarily distributes products in Taiwan.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Ming-ChengChang 3/8/2023 9/30/2015
General Manager Ssu-HsienLi 6/13/2024 11/5/2018
Deputy General Manager-Administration Division, Head of Accounting Yu-PingYang 1/1/2024 8/15/2014
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 103 (As of 12/31/2018)
Outstanding Shares: 328,704,000 (As of 9/30/2024)
Shareholders: 48,739
Stock Exchange: TPO
Fax Number: +886 36684865


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024